- Home
- ESP vs AGEN Comparison
ESP vs AGEN Comparison
Compare ESP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESP | AGEN |
|---|---|---|
| Founded | 1928 | 1994 |
| Country | United States | United States |
| Employees | N/A | 316 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 128.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ESP | AGEN |
|---|---|---|
| Price | $44.43 | $3.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 15.8K | ★ 456.3K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | $42,600,530.00 | ★ $106,829,000.00 |
| Revenue This Year | $9.16 | $67.15 |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $1.38 |
| 52 Week High | $55.00 | $7.34 |
Technical Indicators
Market Signals| Indicator | ESP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 36.60 |
| Support Level | $41.30 | $3.82 |
| Resistance Level | $44.30 | $4.12 |
| Average True Range (ATR) | 1.66 | 0.20 |
| MACD | 0.54 | -0.05 |
| Stochastic Oscillator | 96.27 | 2.27 |
Price Performance
Historical ComparisonAbout ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).